TCGA has significantly impacted cancer treatment by facilitating the development of targeted therapies and precision medicine approaches. For example, the identification of specific mutations in genes like EGFR, BRAF, and ALK has led to the development of targeted drugs that are now used in clinical practice. Additionally, TCGA data has been instrumental in the design of clinical trials that stratify patients based on molecular characteristics, improving the likelihood of trial success and patient outcomes.
